Role of Autophagy and Reactive Oxygen Species in Cancer Treatment

Autophagy is a catabolic process that eliminates damaged and faulty cellular components via lysosomes. It responds to adverse circumstances like nutritional deficiency, hypoxia, and oxidative damage. Reactive oxygen species (ROS) cause oxidative stress, which is a multidimensional chemical that drives various pathophysiological diseases, including cancer. In addition, the autophagy process has a double role, first preventing tumour formation, but later fostering tumour progression. A growing body of research suggests that autophagy and ROS have a complex interplay in which they can either prevent cancer growth or enhance disease genesis. While a combination of autophagy inhibitor and cytotoxic medicines is now being used in cancer treatment, investigating the potential of autophagy inhibitors for overcoming resistance to different anticancer medications and how this relates to the control of cancer micro environmental stressors raises several questions. Autophagy's dual functions as a safeguarding and cytotoxic process have drawn attention to its significance in the development of cancer.

Auteur

Dr. Neeraj Mishra is working as Professor and Head, Department of Pharmaceutics, in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty years of teaching and research experience. He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localized drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders. Dr. Mishra more than 3500 citations with h- index 30. The total cumulative Impact Factor of his published papers is more than 300 (as per SCOPUS). He has also written 10 Books and 25 book chapters in Elsevier, Bentham, Springer and Wiley Publication etc. He has also been granted 3 international patents and 2 Indian patents. Dr. Mishra is recipient of "Distinguished Professor Award" 2019 from DST-NSTMIS, SPAICS, Indore, and M.P. in September 2019. Dr. Mishra has also received the "Outstanding Scientist Award '' 2020, 6th International Scientist Awards on Engineering, Science, and Medicine, 20-21 June 2020, Chennai, India. Dr. Mishra has received the "Distinguished Professor Award '' 2021 from Indian Pharmaceutical Association, MP State Branch, Indore. Dr Mishra has received Best Academician Award in the Indian Pharmacy Graduate Association, M.P. State International Conference held on 06th May 2023 at DAVV Auditorium, Indore, India.

Dr. Mishra worded as guest Editor of Thematic issue entitled "Nanoparticulate Carriers for the treatment of Infectious Diseases and Cancer", Current Molecular Pharmacology, Volume 14, 2021, Issue number 3, Bentham Sciences, IF 3.3. Dr. Mishra got place in Stanford University Scientists Rankings conducted by AD Scientific Index - World Scientists Rankings - 2024 and 2022.

Dr. Ravinder Kumar Kaundal is a highly distinguished researcher in the field of pharmacology and toxicology. He completed his MS (Pharm.) and Ph.D. in Pharmacology and Toxicology at NIPER-SAS Nagar, India, where he developed a strong foundation in the pharmaceutical sciences. Dr. Ravinder is working as Assistant Professor in National Institute of Pharmaceutical Education and Research, Raebareli.